TD Cowen Initiates Coverage On Rapport Therapeutics with Buy Rating
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating, as announced by analyst Joseph Thome.
July 02, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has initiated coverage on Rapport Therapeutics with a Buy rating, indicating a positive outlook on the stock.
The initiation of coverage with a Buy rating by a reputable analyst can lead to increased investor interest and buying activity, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100